Gastrointestinal adverse events and hepatobiliary adverse events were more common in the ceftriaxone group than in the placebo group ( gastrointestinal , 245 of 340 [ 72 % ] ceftriaxone vs 97 of 173 [ 56 % ] placebo , p = 00004 ; hepatobiliary , 211 [ 62 % ] vs 19 [ 11 % ] , p < 00001 ) .